TransMedics: Even After 40% Drop, Still Priced for Perfection – Hold the Sell Stance

What happened

TransMedics stock has declined nearly 40% since October, but a new Seeking Alpha analysis argues it remains overvalued, with the current price still embedding sustained 9–20% revenue growth and 9–17% free cash flow margins – a high bar given decelerating trends. The DeepValue master report, which rates TMDX a Potential Sell with a $135 base case and $105 attractive entry, similarly finds no margin of safety at ~$136, as the stock trades at 50x P/E and 67x EV/EBITDA. Both sources highlight that growth levers such as CHOPS, international expansion, and OPO conversion are either slow-moving, highly uncertain, or merely hedges against a maturing U.S. NOP. The article explicitly calls out that the valuation 'remains hard to justify,' echoing the DeepValue report's thesis that any growth deceleration or adverse regulatory development would trigger multiple compression. Together, these perspectives reinforce that the risk/reward is skewed to the downside despite the recent price drop.

Implication

The combined analysis confirms that TransMedics remains a show-me story. Investors should wait for either a lower entry (sub-$110) or clear evidence that growth can sustain 25%+ with stable margins while legal and regulatory overhangs dissipate. Without that, the upside is limited to ~$190 in a best case, while downside scenarios below $90 are plausible.

Thesis delta

The Seeking Alpha article does not alter the existing sell thesis from the DeepValue report; it reinforces it by highlighting that even after the ~40% drop, the stock is still priced for perfection. The key insight is that the market has not repriced the risks sufficiently – growth deceleration, regulatory overhang, and capital intensity remain underappreciated. Thus, the thesis shifts from 'overvalued at $136' to 'overvalued at $136 even after a significant decline.'